Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review

Document Sample
Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					           Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic SWOT
                                   Analysis Review
        Reference Code: GDPH82226FSA                                                                                          Publication Date: APR 2012

          45 Hartwell Avenue                                 Phone              +1 781 2748200                  Revenue          7.6 (million USD)
          Lexington, MA                                      Fax                +1 781 2748228                  Net Profit       -47.38 (million USD)
          02421                                              Website            www.syntapharma.com             Employees        122
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           SNTA [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Synta Pharmaceuticals Corp. (Synta) is a biopharmaceutical company that discovers, develops and commercializes novel
       pharmaceutical products for the treatment of severe medical conditions such as cancer, autoimmune and chronic inflammatory
       diseases. The company has a unique chemical compound library, an integrated discovery engine and a diverse pipeline of clinical
       and preclinical stage drug candidates. The company mainly operates in the US. Synta is headquartered at Massachusetts, the
       US.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Synta Pharmaceuticals Corp., SWOT Analysis
         Keith R. Gollust                    Chairman                                 Strengths                              Weaknesses
         Dr. Safi R. Bahcall, Ph.D.          Chief Executive Officer
                                                                                      Strong Intellectual Property           Weak Financial Performance
         Bruce Kovner                        Director                                 Portfolio
                                                                                                                             Lack of Marketed Products
         William S. Reardon                  Director
                                                                                      Diverse Pipeline Drug
         Robert N. Wilson                    Director                                 Candidates
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData
                                                                                      Opportunities                          Threats
       Share Data
         Synta Pharmaceuticals Corp.                                                  Strategic Collaborations               Uncertain R&D Outcomes
        Share Price (USD) as on 20-Apr-                                  4.09         Market Potential: Cancer               Intense Competition
        2012
        EPS (USD)                                                     -1.000
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                         225         GlobalData

        Enterprise Value (million USD)                                   211
        Shares Outstanding (million)                                       58
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 12, 2012         Synta Appoints Dvorit           Samid     As    Vice
                                                                                                           President, Medical Affairs
                                                                                      Feb 22, 2012         Synta Pharmaceuticals Reports Revenue Of
                                                                                                           $3.4m In Q4 2011
                                                                                      Nov 03, 2011         Synta Pharmaceuticals Reports Revenue Of
                                                                                                           $1.7m In Q3 2011
                                                                                      Aug 04, 2011         Synta Reports Total Revenue Of $1.3m For
                                                                                                           Q2 2011
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic                                                                   Reference Code: GDPH82226FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Synta Pharmaceuticals Corp. - Key Facts .......................................................................................................................................... 5
       Synta Pharmaceuticals Corp. - Key Employees ................................................................................................................................. 6
       Synta Pharmaceuticals Corp. - Key Employee Biographies ............................................................................................................... 7
       Synta Pharmaceuticals Corp. - Major Products and Services ............................................................................................................ 8
       Synta Pharmaceuticals Corp. - Pharmaceutical Pipeline Products Data ............................................................................................ 9
          Synta Pharmaceuticals Corp., Pipeline Products by Therapy Area ................................................................................................ 9
          Synta Pharmaceuticals Corp., Pipeline Products by Development Phase .................................................................................... 10
       Synta Pharmaceuticals Corp. - History ............................................................................................................................................. 13
       Synta Pharmaceuticals Corp. - Company Statement ....................................................................................................................... 16
       Synta Pharmaceuticals Corp. - Locations And Subsidiaries ............................................................................................................. 22
          Head Office ................................................................................................................................................................................... 22
       Section 2 – Company Analysis ......................................................................................................................................................... 23
       Synta Pharmaceuticals Corp. - Business Description ...................................................................................................................... 23
       Synta Pharmaceuticals Corp. - Corporate Strategy.......................................................................................................................... 24
       Synta Pharmaceuticals Corp. - SWOT Analysis ............................................................................................................................... 25
          SWOT Analysis - Overview........................................................................................................................................................... 25
          Synta Pharmaceuticals Corp. - Strengths ..................................................................................................................................... 25
             Strength - Strong Intellectual Property Portfolio ........................................................................................................................ 25
             Strength - Diverse Pipeline Drug Candidates ............................................................................................................................ 25
          Synta Pharmaceuticals Corp. - Weaknesses ................................................................................................................................ 25
             Weakness - Weak Financial Performance ................................................................................................................................ 25
             Weakness - Lack of Marketed Products .................................................................................................................................... 25
             Weakness - Discontinuation of Apilimod ................................................................................................................................... 26
          Synta Pharmaceuticals Corp. - Opportunities ............................................................................................................................... 26
             Opportunity - Strategic Collaborations....................................................................................................................................... 26
             Opportunity - Market Potential: Cancer ..................................................................................................................................... 26
             Opportunity - Emerging Markets ............................................................................................................................................... 26
          Synta Pharmaceuticals Corp. - Threats ........................................................................................................................................ 27
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 27
             Threat - Intense Competition ..................................................................................................................................................... 27
             Threat - Stringent Government Regulations .............................................................................................................................. 27
       Synta Pharmaceuticals Corp. - Key Competitors ............................................................................................................................. 28
       Section 3 – Company Financial Ratios ............................................................................................................................................. 29
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 29
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 29
       Performance Chart ........................................................................................................................................................................... 31
       Financial Performance...................................................................................................................................................................... 31
       Financial Ratios - Interim Ratios....................................................................................................................................................... 32
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 33
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 34
          Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012.............................................. 34


Synta Pharmaceuticals Corp. (SNTA) - Financial and Strategic                                                                                                   Reference Code: GDPH82226FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Synta Pharmaceuticals Corp., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ............................................. 35
       Synta Pharmaceuticals Corp., Recent Deals Summary ................................................................................................................... 36
       Section 5 – Company’s Recent Developments ................................................................................................................................ 37
          Synta Pharmaceuticals Corp., Recent Developments .................................................................................................................. 37
             Mar 12, 2012: Synta Appoints Dvorit Samid As Vice President, Medical Affairs ....................................................................... 37
             Feb 22, 2012: Synta Pharmaceuticals Reports Revenue Of $3.4m In Q4 2011 ....................................................................... 37
             Nov 03, 2011: Synta Pharmaceuticals Reports Revenue Of $1.7m In Q3 2011 ....................................................................... 39
             Aug 04, 2011: Synta Reports Total Revenue Of $1.3m For Q2 2011 ....................................................................................... 40
             May 05, 2011: Synta Pharmaceuticals Reports Net Loss Of $11.4m For Q1 2011 ................................................................... 41
             Apr 04, 2011: Synta Announces Ganetespib Results At AACR ................................................................................................ 41
             Mar 11, 2011: Synta Reports
				
DOCUMENT INFO
Description: Synta Pharmaceuticals Corp. (Synta) is a biopharmaceutical company that discovers, develops and commercializes novel pharmaceutical products for the treatment of severe medical conditions such as cancer, autoimmune and chronic inflammatory diseases. The company has a unique chemical compound library, an integrated discovery engine and a diverse pipeline of clinical and preclinical stage drug candidates. The company mainly operates in the US. Synta is headquartered at Massachusetts, the US.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.